Patents by Inventor Xincheng Zheng

Xincheng Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20200399345
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Applicant: OncoImmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 10793617
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: October 6, 2020
    Assignee: ONCOIMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20190016783
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: August 16, 2018
    Publication date: January 17, 2019
    Applicant: ONCOLMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20170233453
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: February 21, 2017
    Publication date: August 17, 2017
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 9611309
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: April 4, 2017
    Assignee: Oncolmmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20150239953
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: October 21, 2014
    Publication date: August 27, 2015
    Applicant: Oncolmmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 8895022
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: November 25, 2014
    Assignee: OncoImmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 8808697
    Abstract: Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: August 19, 2014
    Assignee: Oncoimmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20140107322
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: October 16, 2013
    Publication date: April 17, 2014
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
    Patent number: 8637013
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 28, 2014
    Assignee: The Regents of The University of Michigan
    Inventors: Yang Liu, Pan Zheng, Guo-Yun Chen, Xincheng Zheng, Xi Cheng, Steve Kunkel
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20130231464
    Abstract: Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: May 13, 2013
    Publication date: September 5, 2013
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20130136739
    Abstract: Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 30, 2013
    Applicant: ONCOIMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD-24-HMGB1-SIGLEC10 AXIS
    Publication number: 20120201819
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Application
    Filed: March 21, 2012
    Publication date: August 9, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Yang LIU, Pan ZHENG, Guo-Yun CHEN, Xi CHEN, Steve KUNKEL, Xincheng ZHENG
  • Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
    Patent number: 8163281
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: April 24, 2012
    Assignee: The Regents Of The University Of Michigan
    Inventors: Yang Liu, Pan Zheng, Guo-Yun Chen, Xincheng Zheng, Xi Chen, Steve Kunkel
  • TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD24-HMGB1-SIGLEC10 AXIS
    Publication number: 20110064746
    Abstract: The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
    Type: Application
    Filed: March 3, 2010
    Publication date: March 17, 2011
    Inventors: Yang Liu, Pan Zheng, Guo-Yun Chen, Xi Chen, Steve Kunkel, Xincheng Zheng